medRxiv
September 11, 2026
Srdjan Sumarac, Tristan Lawson, Leonardo Favi Bocca et al.
preprint
Ketamine and subcallosal cingulate (SCC) deep brain stimulation (DBS) have each shown antidepressant effects in treatment-resistant depression, yet how ketamine modulates SCC physiology during chronic stimulation remains poorly understood. We analyzed 5,907 hours of bilateral SCC sensing, 485 participant-triggered recordings across 193 days, 47 ketamine dosing episodes, and an in-clinic...
Journal of Psychiatric Research
September 10, 2026
Background: Major depressive and bipolar disorders are leading causes of disability, with many patients developing treatment-resistant depression (TRD/TRBD). Ketamine offers rapid symptom relief, yet recovery extends beyond symptoms. Life engagement (LE) is a key patient-centered outcome encompassing the ability to experience pleasure, function effectively, and participate in meaningful...
Psychiatry International
September 10, 2026
Tommaso Barlattani, Giorgio Sernia, Chiara D’Amelio et al.
Background: Evidence for repeated intranasal esketamine in obsessive–compulsive disorder (OCD) remains preliminary, particularly when OCD co-occurs with treatment-resistant depression (TRD). Methods: We report a 58-year-old woman treated with intranasal esketamine in routine clinical care for TRD; change in obsessive–compulsive symptoms was followed as a secondary observational outcome. Her...
International Journal of Molecular Sciences
September 10, 2026
Xizhen Zhang, Xiaowen Zhang, Haiyu Zhang et al.
Depression, characterized by persistent low mood and anhedonia, represents a prevalent affective disorder imposing substantial medical and economic burdens. Current first-line antidepressants are limited by delayed onset and treatment resistance. Psilocybin (PSI) has re-emerged as a promising therapeutic agent with rapid, sustained antidepressant effects. This systematic review was conducted...
PLoS One
September 9, 2026
J Richard T Korecki, Diana Winston, Elizabeth Ko et al.
Introduction: Nearly 80% of healthcare providers experience adverse psychological symptoms (e.g., depression, burnout, sleep disturbance) stemming from workplace stressors. Elevated levels of stress have been associated with unfavorable occupational, patient, and provider-related outcomes, imposing a heavy burden on a strained system. Given the impact of stress on both employee and patient...
The International Journal of Neuropsychopharmacology
September 9, 2026
Johanna Keeler, Hubertus Himmerich, Janet Treasure et al.
Abstract Background Approximately a third of people with anorexia nervosa (AN) develop a severe and enduring form of the illness, which is often accompanied by depression. This can be a key barrier to recovery. Anti-depressant medications are less effective in treating depression in patients with acute AN, thus new pharmacological treatment options are needed. Ketamine is currently used for...
The International Journal of Neuropsychopharmacology
September 9, 2026
P-C Wu, T-P Su, C-T Li et al.
Abstract Background While ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), response heterogeneity necessitates robust biomarkers to optimize clinical decision-making. Aims & Objectives To validate a machine-learning (ML) framework for predicting ketamine antidepressant response from pre-treatment multimodal neuroimaging features across independent...
The International Journal of Neuropsychopharmacology
September 9, 2026
Rei Yokoyama, M Matsumi, S Asano et al.
Abstract Background The execution of prosocial behaviors requires the ability to accurately understand and infer others’ affective states. Impairments in prosocial functioning have been shown to be associated with the pathology of several psychiatric disorders. In particular, individuals with depression exhibit reduced cognitive and affective responses to others’ emotions. These impairments may...
The International Journal of Neuropsychopharmacology
September 9, 2026
Y-H Chan, H-M Chang
Abstract Background Esketamine, the S-enantiomer of ketamine, is an NMDA receptor antagonist approved for treatment-resistant depression (TRD). Although regulated clinical trials suggest a low risk of misuse, concerns remain that esketamine exposure may facilitate transition to ketamine dependence, particularly in East Asia where illicit ketamine is widely available. Aims & Objectives To...
The International Journal of Neuropsychopharmacology
September 9, 2026
Sota Tomiyama, K Yonezawa, K Kusudo et al.
Abstract Background Cognitive dysfunction is associated with impaired psychosocial functioning in patients with major depressive disorder (MDD). Patients with treatment-resistant depression (TRD) exhibit more pronounced cognitive dysfunction than those with non-resistant MDD, underscoring the need for effective therapeutic strategies. Psilocybin has emerged as a promising treatment for...
The International Journal of Neuropsychopharmacology
September 9, 2026
Z Wang, W Chen, C Hu et al.
Abstract Background Within the rapidly expanding field of psychedelic research, psilocybin, along with its active metabolite psilocin, has emerged as a highly promising candidate in the search for innovative treatments for neuropsychiatric disorders. In this context, preclinical research using animal disease models has produced somewhat inconsistent results when employing standard tests to...
The International Journal of Neuropsychopharmacology
September 9, 2026
Lisa Harada, K Yonezawa, K Kusudo et al.
Abstract Background Despite sequential treatments with conventional antidepressants, many patients with depression experience insufficient clinical improvement, referred to as treatment-resistant depression (TRD). Psilocybin, a serotonergic psychedelic acting as a 5-HT2A receptor agonist, has attracted increasing attention as a novel treatment, with clinical trials demonstrating rapid and...
The International Journal of Neuropsychopharmacology
September 9, 2026
C Zarate
Abstract Background Ketamine produces rapid antidepressant and anti-anhedonic effects in treatment-resistant depression, but response is heterogeneous and mechanisms at the circuit level remain incompletely defined. Convergent imaging work implicates anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), and reward-related networks as key loci for ketamine’s therapeutic and...
The International Journal of Neuropsychopharmacology
September 9, 2026
David Erritzøe
Abstract Background Recent clinical and neuroscientific work has revived interest in psychedelic-assisted therapies as promising treatments for a range of psychiatric conditions. Mechanistically, classical psychedelics and atypical agents such as ketamine appear to act as catalysts of neural and psychological flexibility, disrupting entrenched patterns of activity in “stuck” brain networks and...
The International Journal of Neuropsychopharmacology
September 9, 2026
J Vieira-Andrade, I Marques, M Brito
Abstract Background Serotonin 2A receptor (5-HT2AR) agonists play a crucial role in multiple cognitive processes, namely executive functions, learning and memory. Owing partly to this, psychedelics such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), mescaline and ayahuasca might be valuable adjuvants in improving memory deficits and language impairment. Thanks to...
Harvard Review of Psychiatry
September 8, 2026
Warwick M. Green, Sanket B Raut, F. E. James et al.
There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option. We assessed the current body of MDMA-AT evidence for effectiveness in treating PTSD, associated impairments, and...
Journal of Psychiatric Research
September 7, 2026
Objective: Treatment-resistant depression (TRD) is associated with severe functional impairment, poor quality of life, and increased suicide risk. This study evaluated the effectiveness of intranasal esketamine on depressive symptoms, hopelessness, suicidal ideation, and quality of life in patients with TRD, exploring whether outcomes differed according to concomitant antidepressant class (SSRI...
Neuropsychological rehabilitation
September 7, 2026
Purani Bogahawatta, Ashan Wijekoon, Thameesha Harini et al.
Scientific interest in mindfulness meditation as complementary therapy for Parkinson's disease (PD) has grown significantly. This systematic review examined mindfulness meditation effects on PD motor, cognitive, falls-related (fear of falling (FoF), freezing of gait (FoG), falls prevention), psychological (anxiety and depression), physical (balance, mobility, gait velocity), and quality of life...
Research Square
September 7, 2026
Jennifer L Phillips, Ifeoluwa Olaoluwa, Areebah Ahmed et al.
preprint
Abstract Metabolic, inflammatory, and neurotrophic measures may provide complementary insight into biological heterogeneity underlying treatment-resistant depression and response to ketamine-based treatments. However, biomarker studies of ketamine treatment have focused on individual markers or biological domains, most commonly inflammatory or neurotrophic, while metabolic measures remain...
The World Journal of Biological Psychiatry
September 6, 2026
Balwinder Singh, Siamak MahmoudianDehkordi, Jennifer L. Vande Voort et al.
OBJECTIVE: Ketamine is a rapid-acting antidepressant with an incompletely understood mechanism of action. Pharmacometabolomics can identify pathways underlying its effects and response variability. Using data from the Bio-K trial (NCT03156504), a multisite open-label study, we characterised metabolomic signatures of intravenous (IV) racemic ketamine in adults with treatment-resistant depression...